Harold Shlevin Sells 7,732 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

Posted by Brian Himes on Jul 2nd, 2026

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) Director Harold Shlevin sold 7,732 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $5.00, for a total transaction of $38,660.00. Following the transaction, the director directly owned 6,500 shares in the company, valued at approximately $32,500. This represents a 54.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Galectin Therapeutics Trading Down 6.7%

NASDAQ:GALT opened at $4.33 on Thursday. Galectin Therapeutics Inc. has a 12 month low of $2.03 and a 12 month high of $7.13. The stock has a market capitalization of $285.17 million, a price-to-earnings ratio of -10.56 and a beta of 0.34. The firm has a fifty day simple moving average of $2.69 and a two-hundred day simple moving average of $3.05.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Equities analysts predict that Galectin Therapeutics Inc. will post -0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on GALT. Weiss Ratings upgraded Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. Wall Street Zen raised Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Galectin Therapeutics in a report on Tuesday, June 23rd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $11.00.

Check Out Our Latest Stock Analysis on Galectin Therapeutics

Hedge Funds Weigh In On Galectin Therapeutics

A number of hedge funds have recently added to or reduced their stakes in GALT. Vanguard Group Inc. boosted its position in shares of Galectin Therapeutics by 2.9% during the third quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company’s stock valued at $9,520,000 after buying an additional 63,419 shares during the last quarter. Jane Street Group LLC bought a new position in Galectin Therapeutics during the 2nd quarter valued at $1,580,000. Marshall Wace LLP boosted its holdings in Galectin Therapeutics by 8.6% during the 4th quarter. Marshall Wace LLP now owns 602,134 shares of the company’s stock worth $2,505,000 after acquiring an additional 47,873 shares during the last quarter. Wealthspire Advisors LLC grew its stake in shares of Galectin Therapeutics by 25.5% in the 4th quarter. Wealthspire Advisors LLC now owns 601,973 shares of the company’s stock worth $2,504,000 after acquiring an additional 122,455 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in shares of Galectin Therapeutics by 13.3% in the fourth quarter. Commonwealth Equity Services LLC now owns 334,096 shares of the company’s stock valued at $1,390,000 after purchasing an additional 39,195 shares during the last quarter. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

(Get Free Report)

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.